Abiraterone, Prednisone, Apalutamide Improves Prostate Cancer Outcomes, Leaves HRQoL Unaffected
January 25th 2024Oncological outcomes improved with the addition of abiraterone acetate (Zytiga) plus prednisone (AAP) and apalutamide (Erleada) after radical prostatectomy and did not significantly affect health-related quality of life.